CHP-nanogel cancer vaccines

Complexes of CHP nanoparticles containing a tumor antigen are a new type of cancer vaccine with a novel antigen delivery system that presents multiple epitope peptides via both the MHC class I and class II pathways. We have been developing CHP-protein-based human cancer vaccines that efficiently induce immune responses against multiple T cell epitopes for various HLA types.

CHP-HER2 phase I clinical trial

To target the HER2 antigen, we prepared a truncated HER2 protein containing residues 1?146 (146HER2) complexed with CHP as a CHP-HER2 vaccine. We then designed a clinical study to assess the safety of the vaccine and measure the HER2-specific T-cell immune responses with a newly developed enzyme-linked immunospot assay. Nine patients with various types of solid tumors were enrolled, and the CHP-HER2 vaccine was well tolerated. HER2-specific CD8(+) and/or CD4(+) T-cell immune responses were detected in five patients who received four to eight vaccinations, and both types of T-cell responses were detected in these patients. Among the four patients with CD8(+) T-cell responses, two patients reacted to previously identified HER2(63-71) peptide and the other two reacted only to 146HER2 mRNA-transduced cells (Clin Cancer Res. 2006; 12(24):7397?7405).

CHP-NY-ESO-1 phase I clinical trial

We conducted a dose-escalating trial with the CHP-NY-ESO-1 vaccine at doses of 100 μg and 200 μg in patients with esophageal cancer that was resistant to standard therapies. We evaluated the safety and immune responses to the NY-ESO-1 antigen over the vaccination period, and explored the clinical impact on esophageal cancer patients with poor prognosis. The safety and immunogenicity of CHP-NY-ESO-1 vaccine were confirmed, and the 200 μg dose more efficiently induced immune responses and better survival (J Transl Med. 2013; 11:246).

Summary: Clinical Studies of CHP-NY-ESO-1